TAS-119
N/A
Report date: 2026/03/26 20:00:17
NME
Base Information
Drug NameTAS-119
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications +[13]
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[6]
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTaiho Pharmaceutical Co LtdOtsuka Holdings Co Ltd
China Registration ClassClass 1 Chemical Drug in China
Develop Information
Active CompaniesJs Innopharm LtdShanghai Jiao Tong University School of MedicineMasonic Cancer Center, University Of Minnesota +[6]
Inactive CompaniesVitrac Therapeutics LLCTaiho Oncology Inc
Active Indications +[13]
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A